Impact of Preoperative Erythropoietin on Allogeneic Blood Transfusions in Surgical Patients: Results from a Systematic Review and Meta-analysis

Anesthesia and Analgesia

Volumn 128, Issue 5, 2019, Pages 981-992

  Cho, Brian C ^a   Serini, Jessica ^b   Zorrilla Vaca, Andres ^c   Scott, Michael J ^d   Gehrie, Eric A ^a   Frank, Steve M ^a   Grant, Michael C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD DEL VALLE   (Colombia)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; ANTIANEMIC AGENT; EPO PROTEIN, HUMAN;

CHILL; ELECTIVE SURGERY; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL SURGERY; HEART INFARCTION; HEART SURGERY; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INTRAOPERATIVE PERIOD; LENGTH OF STAY; META ANALYSIS; NAUSEA; OPERATIVE BLOOD LOSS; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN MANIFESTATION; SURGICAL PATIENT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; ALLOTRANSPLANTATION; BLOOD TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; RISK; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; HEMATINICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINS; HOSPITALIZATION; HUMANS; INPATIENTS; PREOPERATIVE PERIOD; RISK; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 85064964941     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000004005     Document Type: Review

References (50)

1. Rohde JM, Dimcheff DE, Blumberg N, Health care-associated infection after red blood cell transfusion: A systematic review and meta-analysis. JAMA. 2014; 311: 1317-1326.
2. Goel R, Patel EU, Cushing MM, Association of perioperative red blood cell transfusions with venous thromboembolism in a North American registry. JAMA Surg. 2018; 153: 826-833.
3. Johnson DJ, Scott AV, Barodka VM, Morbidity and mortality after high-dose transfusion. Anesthesiology. 2016; 124: 387-395.
4. Blaudszun G, Butchart A, Klein AA, Blood conservation in cardiac surgery. Transfus Med. 2018; 28: 168-180.
5. Frank SM, Thakkar RN, Podlasek SJ, Implementing a health system-wide patient blood management program with a clinical community approach. Anesthesiology. 2017; 127: 754-764.
6. Alghamdi AA, Albanna MJ, Guru V, Brister SJ, Does the use of erythropoietin reduce the risk of exposure to allogeneic blood transfusion in cardiac surgery? A systematic review and meta-analysis. J Card Surg. 2006; 21: 320-326.
7. Laupacis A, Fergusson D, Erythropoietin to minimize perioperative blood transfusion: A systematic review of randomized trials. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Transfus Med. 1998; 8: 309-317.
8. Alsaleh K, Alotaibi GS, Almodaimegh HS, Aleem AA, Kouroukis CT, The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty: A meta-analysis of randomized clinical trials. J Arthroplasty. 2013; 28: 1463-1472.
9. Higgins JP, Altman DG, Gøtzsche PC, Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: D5928.
10. Aydin Z, Mallat MJ, Schaapherder AF, Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant. 2012; 12: 1793-1800.
11. Canadian Orthopedic Perioperative Erythropoietin Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet. 1993; 341: 1227-1232.
12. Christodoulakis M, Tsiftsis DD, Hellenic Surgical Oncology Perioperative EPO Study Group. Preoperative epoetin alfa in colorectal surgery: A randomized, controlled study. Ann Surg Oncol. 2005; 12: 718-725.
13. D'Ambra MN, Gray RJ, Hillman R, Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg. 1997; 64: 1686-1693.
14. Dardashti A, Ederoth P, Algotsson L, Erythropoietin and protection of renal function in cardiac surgery (the EPRICS Trial). Anesthesiology. 2014; 121: 582-590.
15. deAndrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC, Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthop. 1996; 25: 533-542.
16. Dousias V, Paraskevaidis E, Dalkalitsis N, Tsanadis G, Navrozoglou I, Lolis D, Recombinant human erythropoietin in mildly anemic women before total hysterectomy. Clin Exp Obstet Gynecol. 2003; 30: 235-238.
17. Dousias V, Stefos T, Navrozoglou I, Staikos I, Ditto A, Paraskevaidis E, Administration of recombinant human erythropoietin in patients with gynecological cancer before radical surgery. Clin Exp Obstet Gynecol. 2005; 32: 129-131.
18. Faris PM, Ritter MA, Abels RI, The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The American Erythropoietin Study Group. J Bone Joint Surg Am. 1996; 78: 62-72.
19. Feagan BG, Wong CJ, Kirkley A, Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med. 2000; 133: 845-854.
20. Gaston KE, Kouba E, Moore DT, Pruthi RS, The use of erythropoietin in patients undergoing radical prostatectomy: Effects on hematocrit, transfusion rates and quality of life. Urol Int. 2006; 77: 211-215.
21. Haljan G, Maitland A, Buchan A, The erythropoietin neuroprotective effect: Assessment in CABG surgery (TENPEAKS): A randomized, double-blind, placebo controlled, proof-of-concept clinical trial. Stroke. 2009; 40: 2769-2775.
22. Heiss MM, Tarabichi A, Delanoff C, Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Surgery. 1996; 119: 523-527.
23. Kateros K, Sakellariou VI, Sofianos IP, Papagelopoulos PJ, Epoetin alfa reduces blood transfusion requirements in patients with intertrochanteric fracture. J Crit Care. 2010; 25: 348-353.
24. Kettelhack C, Hönes C, Messinger D, Schlag PM, Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg. 1998; 85: 63-67.
25. Kim JH, Shim JK, Song JW, Song Y, Kim HB, Kwak YL, Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: A double blind, randomized clinical trial of efficacy and safety. Crit Care. 2013; 17: R254.
26. Kim JE, Song SW, Kim JY, Lee HJ, Chung KH, Shim YH, Effect of a single bolus of erythropoietin on renoprotection in patients undergoing thoracic aortic surgery with moderate hypothermic circulatory arrest. Ann Thorac Surg. 2016; 101: 690-696.
27. Kosmadakis N, Messaris E, Maris A, Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: Prospective randomized double-blind study. Ann Surg. 2003; 237: 417-421.
28. Laupacis A, Effectiveness of perioperative epoetin alfa in patients scheduled for elective hip surgery. Semin Hematol. 1996; 33: 51-53.
29. Luchette FA, Pasquale MD, Fabian TC, Langholff WK, Wolfson M, A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: The long term trauma outcomes study. Am J Surg. 2012; 203: 508-516.
30. Na HS, Shin SY, Hwang JY, Jeon YT, Kim CS, Do SH, Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. Transfusion. 2011; 51: 118-124.
31. Norager CB, Jensen MB, Madsen MR, Qvist N, Laurberg S, Effect of darbepoetin alfa on physical function in patients undergoing surgery for colorectal cancer. A randomized, double-blind, placebo-controlled study. Oncology. 2006; 71: 212-220.
32. Podestà A, Carmagnini E, Parodi E, Elective coronary and valve surgery without blood transfusion in patients treated with recombinant human erythropoietin (epoetin-alpha). Minerva Cardioangiol. 2000; 48: 341-347.
33. Qvist N, Boesby S, Wolff B, Hansen CP, Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: Reduced need for blood transfusions in patients undergoing colorectal surgery-prospective double-blind placebo-controlled study. World J Surg. 1999; 23: 30-35.
34. Scott SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH, The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: A prospective, randomized, placebo-controlled study. Laryngoscope. 2002; 112: 1221-1229.
35. Sowade O, Ziemer S, Sowade B, The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery. J Lab Clin Med. 1997; 129: 376-383.
36. Sowade O, Warnke H, Scigalla P, Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood. 1997; 89: 411-418.
37. Tsuji Y, Kambayashi J, Shiba E, Sakon M, Kawasaki T, Mori T, Effect of recombinant human erythropoietin on anaemia after gastrectomy: A pilot study. Eur J Surg. 1995; 161: 29-33.
38. Weber EW, Slappendel R, Hémon Y, Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: The European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol. 2005; 22: 249-257.
39. Weltert L, D'Alessandro S, Nardella S, Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: A randomized blind controlled study. J Thorac Cardiovasc Surg. 2010; 139: 621-626.
40. Weltert L, Rondinelli B, Bello R, A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: Results of a prospective single-blind randomized controlled trial. Transfusion. 2015; 55: 1644-1654.
41. Wurnig C, Schatz K, Noske H, Collaborative Study Group. Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation. Eur Surg Res. 2001; 33: 303-310.
42. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL, Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology. 2011; 115: 929-937.
43. Corwin HL, Gettinger A, Pearl RG, EPO Critical Care Trials Group. Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA. 2002; 288: 2827-2835.
44. US Food & Drug Administration. Information on Erythropoiesis-Stimulating Agents (ESA) Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp). April 2017. Available at: Https://www.fda.gov/Drugs/DrugSafety/ucm109375.htm. Accessed June 15, 2018.
45. Mazer CD, Whitlock RP, Fergusson DA, TRICS Investigators and Perioperative Anesthesia Clinical Trials Group. Restrictive or liberal red-cell transfusion for cardiac surgery. N Engl J Med. 2017; 377: 2133-2144.
46. Robich MP, Koch CG, Johnston DR, Trends in blood utilization in United States cardiac surgical patients. Transfusion. 2015; 55: 805-814.
47. Gustafsson UO, Scott MJ, Schwenk W, Enhanced Recovery After Surgery Society. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr. 2012; 31: 783-800.
48. Lassen K, Soop M, Nygren J, Enhanced Recovery After Surgery (ERAS) Group. Consensus review of optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) Group recommendations. Arch Surg. 2009; 144: 961-969.
49. Kim JY, Khavanin N, Rambachan A, Surgical duration and risk of venous thromboembolism. JAMA Surg. 2015; 150: 110-117.
50. Mehta KD, Patel S, Patel K, Wang H, Parikh RA, Smith RE, Trends of inpatient venous thromboembolism rates in United States before and after surgeon general's call to action. Blood. 2016; 128: 1177.